Trials / Active Not Recruiting
Active Not RecruitingNCT05479708
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Postoperative ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma: A Prospective Observational Cohort Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- BAIYONG SHEN · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable biomarker to identify those individuals with high risk of recurrence and inform therapeutic decision making. In this study, we aim to examine whether postoperative circulating tumor DNA (ctDNA) could be used as a biomarker for early detection of minimal residual disease (MRD) and predicting relapse in resected PAAD through high-depth targeted next-generation sequencing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ctDNA-based MRD detection | Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit |
Timeline
- Start date
- 2023-08-09
- Primary completion
- 2028-01-01
- Completion
- 2028-08-01
- First posted
- 2022-07-29
- Last updated
- 2026-04-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05479708. Inclusion in this directory is not an endorsement.